OncoMatch/Clinical Trials/NCT03463252
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Is NCT03463252 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Progesterone and Mirena® for endometrial cancer.
Treatment: Progesterone · Mirena® · GnRH agonist — Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Biomarker criteria
Required: PR (PGR) positive (positive)
Disease stage
Required: Stage 1A
Grade: 1
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03463252 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require PGR?
Yes, PGR positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage 1A is required.
Is there an age limit?
Yes. Patients must be 40 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages